ETCTN 10553: Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers (clinicaltrials.gov) - Jun 12, 2026 - P2 | N=21 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Apr 2027 ➔ Nov 2026 | Trial primary completion date: Apr 2027 ➔ Nov 2026
Trial completion date • Trial primary completion date • Oncology • Salivary Gland Cancer
|